Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as
blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to …

Simple Summary Lung cancer is the leading cause of cancer death worldwide. Detecting
lung malignancies promptly is essential for any anticancer treatment to reduce mortality and …

Liquid biopsy has emerged as a promising avenue for non‐invasive and rapid retrieval of
pathological information from patient body fluids. Over the years, liquid biopsy has garnered …

Circulating tumor cells (CTCs) have substantial clinical implications in cancer diagnosis and
monitoring. Although significant progress has been made in developing technologies for …

Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most
patients present with advanced stage disease, which is often associated with poor survival …

Lung cancer is the leading cause of cancer-related deaths worldwide and in China.
Screening for lung cancer by low dose computed tomography (LDCT) can reduce mortality …

Liquid biopsy, an innovative method for early diagnosis of cancer, has changed the
traditional method of diagnosing lung cancer and is considered a feasible auxiliary …

Circulating genetically abnormal cells (CACs) constitute an important biomarker for cancer
diagnosis and prognosis. This biomarker offers high safety, low cost, and high repeatability …

Recent studies have suggested that circulating tumor cells with abnormalities in gene copy
numbers in mononuclear cell‐enriched peripheral blood samples, such as circulating …

Background Lung cancer has the highest mortality rate among malignancies globally. In
addition, due to the growing number of smokers there is considerable concern over its …